Talampanel (INN; development codes GYKI 537773 and LY300164) is a drug which has been investigated for the treatment of epilepsy,[1][2] malignant gliomas,[3] and amyotrophic lateral sclerosis (ALS).[4]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.230.001 |
Chemical and physical data | |
Formula | C19H19N3O3 |
Molar mass | 337.379 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
As of May 2010, results from the trial for ALS have been found negative.[5] Talampanel is not currently under development.
Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of ionotropic glutamate receptor in the central nervous system.[6]
It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.[7]